Background: Extracorporeal photopheresis is an immunomodulatory technique i
n which a patient's leukocytes are exposed to ultraviolet-A light after pre
treatment with 8-methoxypsoralen (methoxsalen). There have been few reports
describing the use of extracorporeal photopheresis in lung transplant reci
pients. Methods: We reviewed our experience using extracorporeal photophere
sis in 8 lung transplant recipients since 1992. All 8 patients had progress
ively decreasing graft function and 7 were in bronchiolitis obliterans synd
rome grade 3 before the initiation of photopheresis. One patient had underg
one a second transplant operation for obliterative bronchiolitis. Two patie
nts had a pretransplantation diagnosis off chronic obstructive pulmonary di
sease, 1 alpha(1)-antitrypsin deficiency, 1 cystic fibrosis, 1 bronchiectas
is, 1 idiopathic pulmonary fibrosis, and 2 primary pulmonary hypertension.
Before refractory rejection developed, all patients had been treated with 3
-drug immunosuppression and anti-T-cell therapy. The median time from trans
plantation to the start of extracorporeal photopheresis was 16.5 months and
the median number of treatments was 6, Results: The condition of 5 of 8 pa
tients subjectively improved after extracorporeal photopheresis therapy, In
these 5 patients photopheresis was associated with stabilization of the fo
rced expiratory volume in 1 second. In 2 patients there was histologic reve
rsal of rejection after photopheresis, With a median follow-up of 36 months
, 7 patients are alive and well. Three patients required retransplantation
at a median of 21 months after completion of the treatments. Four patients
have remained in stable condition after photopheresis. There were no compli
cations related to extracorporeal photopheresis. Conclusion: We believe tha
t this treatment is a safe option for patients with refractory lung allogra
ft rejection when increased immunosuppression is contraindicated or ineffec
tive.